ClinicalTrials.gg
Active, not recruitingNCT07473232KOA PRP ACSUpdated Nov 9, 2026

Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS)

An interventional study of Autologous Platelet-Rich Plasma (PRP) and Conditioned serum (CS) in Knee Arthritis Osteoarthritis, Platelet Rich Plasma Injection and Conditioned Serum, sponsored by Pamukkale University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Pamukkale University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing platelet rich plasma in Osteoarthritis, Knee — 3 open to participants now, 4 under way, 1 of them phase 3. platelet rich plasma · Osteoarthritis, Knee.

Planned enrollment
21st of 43
60 · median 60
Started
2026
the only one that year
No phase
14 of 43
1 open now
Registered
42nd of 43
by date

Among the 43 studies testing platelet rich plasma in Osteoarthritis, Knee, this one is the 21st largest by planned enrollment, is the only one that started in 2026, is one of 14 with no phase, and was the 42nd registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 43 studies testing platelet rich plasma in Osteoarthritis, Knee are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About platelet rich plasma

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing platelet rich plasma in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

The effects of single dose injection of platelet rich plasma or conditioned serum in the knee joint in patients with knee osteoarthritis will be compared

Read the detailed description

Patients with early grade bilateral knee osteoarthritis (Kellgren Lawrence grade 1 or 2) will be divided into 2 groups. One group of patients will be injected with single dose of autologous platelet rich plasma (PRP) in the knee joints. Other group of patients will be injected with eqiuvolume of autologous conditioned serum (CS) (also known as activated cytokine rich serum) in the knee joints. Patients' serum before injection, the treatment product (PRP and CS), patients serum 30 min after injection will be investigated for IL-1β, IL-1Ra, PDGF-BB, IGF-1, TGF-β and TNF-α. Patients' serum 1 week and 1 month after injection will be investigated for MMP-13, COMP by ELISA. Patients will also be investigated for visual pain scale, WOMAC (Western Ontorino and Mc Master) scale range of motion, ultrasonographic tibiofemoral cartilage thickness measurement and functional tests including the 30-second chair test, stair climb test, 40 meter fast paced walk test, timed up and go test, 6-minute walk test, and walking speed in the first week, first month and third month after injection.

03

Conditions studied

  • Knee Arthritis Osteoarthritis
  • Platelet Rich Plasma Injection
  • Conditioned Serum

Keywords

  • knee osteoarthritis
  • platelet rich plasma injection
  • conditioned serum injection
  • inflammation
  • cartilage
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of knee osteoarthritis according to ACR criteria at least 6 months ago.
  2. Being between grade 1-2 according to the Kellgren-Lawrence radiological classification.
  3. Not having had PRP injection in the last year.
  4. Knee pain ≥ 5 according to the visual pain scale.

Exclusion criteria

Exclusion Criteria:

  1. Those with significant neurological or cardiovascular disorders.
  2. Those with active thrombovascular disease.
  3. Those with joint or skin infections.
  4. Those who have recently had an infectious disease.
  5. Those infected with , C, and .
  6. Those who have received intra-articular knee injections (hyaluronic acid, PRP, , and others) within the last year.
  7. Those who use oral corticosteroids.
  8. Those who have used NSAIDs within the last week.
  9. Those who have used anti- or anti-aggregant drugs within the last week.
  10. Those with coagulation disorders.
  11. Those with \<10 g/dl and platelet count \<100,000
  12. Those with cancer.
  13. Pregnant or breastfeeding women, drug addicts.
  14. Those scheduled for knee surgery or arthroscopy, or those who have undergone knee surgery or arthroscopy.
  15. Those with diseases causing secondary osteoarthritis:

    1. post-traumatic,
    2. congenital or developmental diseases

      1. Local diseases (leg length discrepancy, varus, valgus deformities, hypermobility syndromes, scoliosis)
      2. Generalized diseases (Bone dysplasias, Metabolic disorders (hemochromatosis, ochronosis, Gaucher disease, hemoglobinopathy, Ehlers-Danlos disease))
    3. Calcium storage diseases (calcium pyrophosphate storage disease, etc.)
    4. Other bone and joint diseases (avascular necrosis, rheumatoid arthritis, gouty arthritis, septic arthritis, Paget's disease, osteoporosis, osteochondritis)
    5. Other diseases

      1. Endocrine diseases (Diabetes mellitus, acromegaly, hypothyroidism, hyperthyroidism)
      2. Neuropathic arthropathy (Charcot joint)
      3. Other (Frost, Kashin-Beck disease, Caisson disease) -
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    PRP group

    patients with knee osteoarthritis who will be injected with autologous PRP

    Drug: Autologous Platelet-Rich Plasma (PRP)

  • Experimental
    conditioned serum group

    patients with knee osteoarthritis who will be injected with autologous conditioned serum

    Drug: Conditioned serum (CS)

Interventions

  • DrugPlatelet rich plasmaStudies of Platelet rich plasmaPlatelet rich plasma pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Autologous Platelet-Rich Plasma (PRP) will be injected intra-articularly in patients with knee osteoarthritis

  • DrugConditioned serum (CS)

    Autologous conditionedserum (CS) will be injected intra-articularly in patients with knee osteoarthritis

06

What researchers measure

Primary outcomes

  1. Visual pain scale score

    Visual pain scale score (min 0-max 10), higher scores indicate better results

    Time frame: Visual pain scale score (min 0-max 10) will be measured at the beginning ofthe study, 1 week, 1month and 3 months after the injection.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — IPD will bw shared by the primary investigator upon personel contact.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be shared until 3 years after the publication.

Access criteria: Researchers will be able to access upon personel caontavt by e-mail of the primary investgator.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 9 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Aug 2026 → Jan 2027 and completion Oct 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 16, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Jan 18, 2027was Aug 2026
CompletionEst.
Feb 27, 2027was Oct 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 9, 2026
Primary completion
Aug 30, 2026→Jan 18, 2027
Nov 9, 2026
Study completion
Oct 30, 2026→Feb 27, 2027
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Active, not recruiting
    Primary completion Aug 30, 2026→Jan 18, 2027
    Study completion Oct 30, 2026→Feb 27, 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07473232
Responsible party
GULIN FINDIKOGLU (PROFESSOR GULIN FINDIKOGLU MD, PhD, Pamukkale University) — Principal investigator
First posted
Mar 16, 2026
Start date
Apr 1, 2026
Primary completion
Jan 18, 2027 (estimated)
Completion
Feb 27, 2027 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Platelet rich plasma

Start the discussion